Franzelsep den man bei allen Fragen immer fragen sollte es kommt immer eine Konstrutive antwort bei raus.
 

Derzeit keine News aus dem Unternehmen auch auf nachfrage per mail.

Zu bemerken im Kurs  

Seit Tagen leichte Bewegung aufwärts.

Sollte man nachlegen?  

 

https://de.wikipedia.org/wiki/Algorithmus  

sollte man echt den Stecker ziehen ... sie fangen an Wirrwarr zu schreiben.  

Einige entdecken noch die Börse und googel zuviel  

Was war noch dein Einstiegs Kurs?  

Wann kommen weitere Nachrichten zu den Phasen  

Mit Partnern  

Erstmal Sommerpause
Q4 wird intransparent  

 

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things. The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes about 29 countries in Europe and Asia, including Russia, depending on the compound.  

Planung wie die Partnerschaft ausgebaut werden kann  

die Partner haben und wir haben Fördermittel. Aber nix aber auch garnicht zur WP Reihe oder sonstiges. Ich glaube langsam, das Ding ist ein Betrug.  

 

Unternehmen im Sommerloch nächsten möglichen Termine Werder nach den neusten Ergebnissen mitgeteilt

Bleiben Sie  

Es ist Sommerferien auch in Polen  

Nimm die Finger von der Tastatur und mach bitte was anderes mit deinen Fingern. Danke  

Für Dein Hinweis passt nur nicht hier her  

WPD Pharmaceuticals Inc (OTCMKTS: WPDPF) announced that CNS Pharmaceuticals Inc (NASDAQ: CNSP) received a Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its investigational lead drug, Berubicin.
Designation permits company to frequent interactions with FDA

Berubicin is used for the management of patients with recurring glioblastoma multiforme (GBM). As previously reported, CNS had also received Orphan Drug Designation from the FDA for Berubicin to manage patients with recurring GBM.

The Fast Track Designation permits more recurrent communications with the FDA to accelerate the expansion and appraisal procedure for drugs envisioned to treat severe or life-threatening disorders and validate the possibility of tackling unmet medical requirements.

Getting Fast Track Designation from the U.S. FDA is considerable attainment in the progression of Berubicin for the management of glioblastoma, the most belligerent, lethal, and treatment-resistant type of cancer that customs in the brain. Many patients have almost no expressive opportunities, and thousands lose the fight against this cancer every year. With this description, CNS now has an enhanced pathway to endorsing Berubicin and a clear opening to bring this hypothetically impactful untried treatment more advantageously.

CNS recently announced the beginning of patient registration in its revision of Berubicin to manage recurring glioblastoma multiforme. WPD would meaningfully profit from the progression of Berubicin as an action for GBM as it has the privileges to produce and trade the drug applicant in 29 nations.
WPD Pharmaceuticals to borrow up to $150,000

WPD Pharmaceuticals sp. z.o.o. its Polish subsidiary has agreed to derive up to $150,000 from both companies, each organized by insiders. The advances bear interest at 10% per annum and ripe on April 2, 2022. The advances are not translatable to stocks. Therefore, the insider advances are exempted from the estimate and minority stockholder consent necessities.  

Medulloblastoma Pipeline: Clinical Trial, Emerging Therapies and Key pharma players involved by DelveInsight | Oncurious, Y-mAbs Therapeutics, Senhwa Biosciences, Sun Pharmaceutical, Roche and Others

Medulloblastoma is a cancerous brain tumor that starts in the lower back part of the brain, called the cerebellum. Medulloblastoma accounts for nearly 10% of all childhood brain tumors. These tumors occur exclusively in the posterior fossa and have the potential for leptomeningeal spread. Signs and symptoms of medulloblastoma may include headaches, nausea, vomiting, tiredness, dizziness, double vision, poor coordination and unsteady walk. Medulloblastoma is diagnosed based upon thorough clinical and neurological evaluation, detection of characteristic symptoms and physical findings, patient history, and specialized diagnostic tests.

DelveInsight’s, “Medulloblastoma Pipeline Insight, 2021,” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Medulloblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Request for free sample report: https://www.delveinsight.com/sample-request/...stoma-pipeline-insight

Some of Medulloblastoma Companies are:

   Oncurious
   Y-mAbs Therapeutics
   Senhwa Biosciences
   Sun Pharmaceutical Industries
   Roche
   Nelum
   WPD Pharmaceuticals
   Midatech
   Kintara Therapeutics
   VBI Vaccines
   Oncoheroes Biosciences
   And Many Others
 

sieht jedenfalls so aus.  

es wird auch ein gekauft  

 

Bitte nicht nachmachen